Greg Bosch brings more than 35 years of leadership experience in the life sciences across pharmaceuticals, biologics, biosurgery, and medical devices. He has served as CEO of multiple healthcare companies, leading global commercial, operations, and R&D organizations, and has extensive experience in public and private company acquisitions, financings, and initial public offerings.

Prior to founding Persevere Therapeutics, Greg has led organizations through key value-creation milestones, including advancing drug candidates from early development into clinical studies and achieving market leadership positions in regenerative medicine. His prior roles include CEO of Panavance Therapeutics, CEO of Geistlich Pharma North America, and President and CEO of PuriCore PLC, where he led a successful IPO on the London Stock Exchange. Earlier in his career, he held senior leadership roles at Baxter International including General Manager of BioSurgery with international assignments in Europe. Greg holds a B.A. in Public Policy from Duke University and an MBA from DePaul University.